MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis - 09/10/21
, Yi-Tao Xue d, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 12 |
| Iconographies | 8 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
MCC950, an NLRP3 inflammasome inhibitor, displays multiple pharmacological properties. However, the protective potential and underlying mechanism of MCC950 against doxorubicin (DOX)-induced myocardial injury has not been well investigated yet. Herein, DOX-induced myocardial injury in mice and in H9c2 myocardial cells was investigated, and the protective effects and underlying mechanism of MCC950 were fully explored. The results showed that MCC950 co-treatment significantly improved myocardial function, inhibited inflammatory and myocardial fibrosis, and attenuated cardiomyocyte pyroptosis in DOX-treated mice. Mechanismly, MCC950 had the potential to inhibit DOX-induced the cleavage of NLRP3, ASC, Caspase-1, IL-18, IL-1β and GSDMD in vivo. Moreover, MCC950 co-treatment in vivo suppressed DOX-induced cytotoxicity as well as inflammatory and cardiomyocyte pyroptosis through the same molecular mechanism. Taken together, our findings validated that MCC950, an NLRP3 inflammasome inhibitor, has the potential to attenuate doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis.
Le texte complet de cet article est disponible en PDF.Highlights |
• | MCC950 alleviates DOX-induced myocardial dysfunction and inflammation in vivo. |
• | MCC950 attenuates DOX-induced myocardial injury by blocking cardiomyocyte pyroptosis in vivo. |
• | MCC950 inhibits DOX-induced cardiotoxicity in vitro through inhibiting NLRP3-mediated pyroptosis in vitro. |
Keywords : MCC950, Doxorubicin, Myocardial injury, NLRP3 inflammasome, Inflammatory, Pyroptosis
Plan
Vol 143
Article 112133- novembre 2021 Retour au numéro
Article précédent
- Curcumin analogue C66 attenuates obesity-induced myocardial injury by inhibiting JNK-mediated inflammation
- Lin Ye, Xiaojun Chen, Minxiu Wang, Leiming Jin, Zaishou Zhuang, Daona Yang, Xinfu Guan, Aleksandr V. Samorodov, Valentin N. Pavlov, Nipon Chattipakorn, Jianpeng Feng, Yi Wang, Wu Luo, Guang Liang
- Rebound effects of NCX3 pharmacological inhibition: A novel strategy to accelerate myelin formation in oligodendrocytes
- Mariarosaria Cammarota, Valeria de Rosa, Anna Pannaccione, Agnese Secondo, Valentina Tedeschi, Ilaria Piccialli, Ferdinando Fiorino, Beatrice Severino, Lucio Annunziato, Francesca Boscia
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?